The expression of FHL2 is significantly elevated in certain malignant tumors, including cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD), LUSC, and pancreatic adenocarcinoma (PAAD). Here, FHL2 is linked to cholangiocarcinoma.